Peter Argenta, MD - Fairview Health Services
 
Print
Peter Argenta, MD
Peter Argenta, MD
Request Appointment
Gynecologic Cancer Clinic
Phillips-Wangensteen Building
First Floor, Clinic 1C
516 Delaware St. SE
Minneapolis, MN 55455
612-626-3444
 

Sees Patients at:

Philosophy of Care:

I believe in the use of minimally invasive surgery when possible. I make a point of making clinical trials available to all patients with cancer.

Medical Title:

Academic Appointments:

Services:

Specialties:

Clinical Interests:

Languages Spoken:

Education:

Board Certifications:

"Best Doctors for Women" Minnesota Monthly Magazine 2013

U.S. News & World Report
2012 Top Doctor

Mpls. St. Paul Magazine "Top Doctor" - (2012, 2014)

CREOG best faculty teaching award – University of Minnesota July, 2009

“Best Doctors for Women” Minnesota Monthly magazine. February, 2007

Center of Clinical Excellence - Gynecologic Oncology - Park Nicollet Health System

Medical Director 2007 – Highest patient-rated service in the health system

“America’s Top Obstetricians and Gynecologists” Consumers’ Research Council of America. May 2007

“Best Doctors for Women” Minnesota Monthly magazine. May, 2007

“100 Best Doctors for Women” In Minnesota Monthly magazine. March, 2006

Center for Minimally Invasive Surgery, Leadership council – 2002-present

Mount Sinai School of Medicine Award Excellence in Medical School Teaching: Nominee – 2000

Penn Pearls Resident Teaching Award: winner – 1998

Penn Pearls Resident Teaching Award: nominee – 1997

Medical School Honor Performance in Experimental Medicine – 1994

President’s Advisory Council University of Michigan – 1991

Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker.Derycke MS, Pambuccian SE, Gilks CB, Kalloger SE, Ghidouche A, Lopez M, Bliss RL, Geller MA, Argenta PA, Harrington KM, Skubitz AP. Am J Clin Pathol. 2010 Nov;134(5):835-45.PMID: 20959669 [PubMed - indexed for MEDLINE]Related citations

The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer. Kothari R, Nagel C, Koopmeiners JS, Ivy JJ, Geller M, Salani R, Argenta PA. Gynecol Oncol. 2010 Dec;119(3):491-5.PMID: 20888625 [PubMed - in process]Related citations

A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS. Cytotherapy. 2010 Sep 20. [Epub ahead of print]PMID: 20849361 [PubMed - as supplied by publisher]Related citations

Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. Geller MA, Cooley S, Argenta PA, Downs LS, Carson LF, Judson PL, Ghebre R, Weigel B, Panoskaltsis-Mortari A, Curtsinger J, Miller JS. Cancer Immunol Immunother. 2010 Dec;59(12):1877-84. Epub 2010 Sep 5.PMID: 20820775 [PubMed - indexed for MEDLINE]Related citations

A single institution experience using sequential multi-modality adjuvant chemotherapy and radiation in the "sandwich" method for high risk endometrial carcinoma. Geller MA, Ivy J, Dusenbery KE, Ghebre R, Isaksson Vogel R, Argenta PA. Gynecol Oncol. 2010 Jul;118(1):19-23. Epub 2010 Apr 8.PMID: 20381136 [PubMed - indexed for MEDLINE]Related citations

S100A1 expression in ovarian and endometrial endometrioid carcinomas is a prognostic indicator of relapse-free survival. DeRycke MS, Andersen JD, Harrington KM, Pambuccian SE, Kalloger SE, Boylan KL, Argenta PA, Skubitz AP. Am J Clin Pathol. 2009 Dec;132(6):846-56.PMID: 19926575 [PubMed - indexed for MEDLINE]Related citations

Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience. Ivy JJ, Geller M, Pierson SM, Jonson AL, Argenta PA. Gynecol Oncol. 2009 Sep;114(3):420-3. Epub 2009 Jun 26.PMID: 19560189 [PubMed - indexed for MEDLINE]Related citations

A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Argenta PA, Thomas SG, Judson PL, Downs LS Jr, Geller MA, Carson LF, Jonson AL, Ghebre R. Gynecol Oncol. 2009 May;113(2):205-9. Epub 2009 Feb 23.PMID: 19239974 [PubMed - indexed for MEDLINE]Related citations

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De Geest K, Mutch DG, Burger RA, Swart AM, Trimble EL, Accario-Winslow C, Roth LM. J Clin Oncol. 2009 Mar 20;27(9):1419-25. Epub 2009 Feb 17. Erratum in: J Clin Oncol. 2009 May 1;27(13):2305. PMID: 19224846 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

Vulvar cancer in young women: demographic features and outcome evaluation. Lanneau GS, Argenta PA, Lanneau MS, Riffenburgh RH, Gold MA, McMeekin DS, Webster N, Judson PL. Am J Obstet Gynecol. 2009 Jun;200(6):645.e1-5. Epub 2009 Mar 16.PMID: 19286150 [PubMed - indexed for MEDLINE]Related citations

 
 Visit Other Fairview Sites 
 
 
(c) 2012 Fairview Health Services. All rights reserved.